Quarterly report pursuant to Section 13 or 15(d)

Shareholders' Equity (Details 2)

v3.20.2
Shareholders' Equity (Details 2) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Total research and development expenses $ 1,847,178 $ 864,280 $ 3,789,800 $ 2,761,630
Total general and administrative expenses 1,491,173 881,462 3,667,588 3,392,388
Total stock-based compensation expense     1,644,077 1,133,333
Stock Options [Member]        
Research and development options expense 56,458 99,612 196,976 241,315
Total research and development expenses 56,458 99,612 196,976 241,315
General and administrative options expense 291,727 214,007 878,864 511,664
Stock and warrants issued to consultants and employees 329,807 71,250 685,238 380,354
Total general and administrative expenses 621,534 285,257 1,564,102 892,018
Total stock-based compensation expense $ 677,992 $ 384,869 $ 1,761,078 $ 1,133,333